AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles (Arm C)
Number of subjects: 0
Study 34538402 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring (Arm A)
Number of subjects: 0
Study 34538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (Arm B)
Number of subjects: 0
Study 34538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Arm C)
Number of subjects: 0
Study 33950573 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 32000825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol at a target dose of 100 mg per day
Number of subjects: 1700
Study 32000825 — intervention group
Group type: COMPARATOR
Intervention: Standard COPD care only
Number of subjects: 1700
Study 34564893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1100
Study 34564893 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1100
Study 33535060 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping cloth masks while speaking
Number of subjects: 13
Study 33535060 — intervention group
Group type: COMPARATOR
Intervention: No taping of cloth masks while speaking
Number of subjects: 13
Study 33535060 — intervention group
Group type: COMPARATOR
Intervention: Taping cloth masks during normal or deep breathing
Number of subjects: 13
Study 33535060 — intervention group
Group type: COMPARATOR
Intervention: Taping surgical or N95 masks
Number of subjects: 13
Study 35670036 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus low-dose SNK01 (2 × 10^9 cells/dose)
Number of subjects: 20
Study 35670036 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus high-dose SNK01 (4 × 10^9 cells/dose)
Number of subjects: 20
Study 35670036 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab monotherapy
Number of subjects: 20
Study 35670036 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus SNK01
Number of subjects: 20
Study 34030638 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt group (n=479)
Number of subjects: 961
Study 34030638 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=482)
Number of subjects: 961
Study 33242419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 33242419 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (up to 100 mg twice daily)
Number of subjects: 141
Study 33242419 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (up to 100 mg twice daily)
Number of subjects: 141
Study 33242419 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 10 mg twice daily)
Number of subjects: 141
Study 32080092 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES+SWD and supervised exercises
Number of subjects: 20
Study 32080092 — intervention group
Group type: COMPARATOR
Intervention: Sham group with supervised exercise alone
Number of subjects: 20
Study 35867627 — intervention group
Group type: EXPERIMENTAL
Intervention: MBE plus lid hygiene
Number of subjects: 50
Study 35867627 — intervention group
Group type: COMPARATOR
Intervention: Lid hygiene alone
Number of subjects: 50
Study 33588378 — intervention group
Group type: COMPARATOR
Intervention: Presleep protein ingestion (40 g intrinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine-labeled casein protein)
Number of subjects: 36
Study 33588378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus presleep protein ingestion (40 g intrinsically-labeled casein protein after resistance-type exercise)
Number of subjects: 36
Study 35888667 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Voluntary Isometric Contraction (MVIC)
Number of subjects: 328
Study 35888667 — intervention group
Group type: EXPERIMENTAL
Intervention: MVIC-based prediction of 1RM
Number of subjects: 328
Study 34686472 — intervention group
Group type: EXPERIMENTAL
Intervention: R-miniCHOP chemoimmunotherapy with oral azacitidine (CC-486)
Number of subjects: 422
Study 34686472 — intervention group
Group type: COMPARATOR
Intervention: R-miniCHOP chemoimmunotherapy without oral azacitidine (CC-486)
Number of subjects: 422
Study 32469156 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 32469156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study 35986303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SIT)
Number of subjects: 0
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen/1,000 mg acetaminophen
Number of subjects: 600
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen/1,000 mg acetaminophen
Number of subjects: 600
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg codeine/300 mg acetaminophen
Number of subjects: 600
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hydrocodone/300 mg acetaminophen
Number of subjects: 600
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone/325 mg acetaminophen
Number of subjects: 600
Study 33358232 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (codeine, hydrocodone, oxycodone)
Number of subjects: 600
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous amoxicillin and clavulanic acid
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanic acid administration
Number of subjects: 3225
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Episiotomy
Number of subjects: 3225
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 3225
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Primiparity
Number of subjects: 3225
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Body mass index of 25.0 to 29.9 kg/m2
Number of subjects: 3225
Study 36027955 — intervention group
Group type: COMPARATOR
Intervention: Body mass index of ≥30 kg/m2
Number of subjects: 3225
Study 36027955 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of antibiotic administration
Number of subjects: 3225
Study 33108743 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP) aerobic training
Number of subjects: 39
Study 33108743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Periodization (NLP) aerobic training
Number of subjects: 39
Study 32245518 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical antegrade modular pancreatosplenectomy (RAMPS)
Number of subjects: 0
Study 32245518 — intervention group
Group type: COMPARATOR
Intervention: Standard retrograde pancreatosplenectomy (SRPS)
Number of subjects: 0
Study 35794079 — intervention group
Group type: EXPERIMENTAL
Intervention: HN0037 (10, 30, 60, 120, 200, 300, and 400 mg single doses; 30 and 100 mg once daily for 14 days)
Number of subjects: 0
Study 35794079 — intervention group
Group type: COMPARATOR
Intervention: HN0037
Number of subjects: 0
Study 33752121 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin levels
Number of subjects: 0
Study 33752121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca125, HE4, and ROMA levels
Number of subjects: 0
Study 34110862 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple olfactory training (OT) utilizing single-molecule odors
Number of subjects: 68
Study 34110862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures olfactory training (OT) using odor mixtures
Number of subjects: 68
Study 34110862 — intervention group
Group type: COMPARATOR
Intervention: Control group without OT
Number of subjects: 68
Study 34740836 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement (MD) alone
Number of subjects: 88
Study 34740836 — intervention group
Group type: EXPERIMENTAL
Intervention: MD at baseline followed by a single session of adjunct aPDT
Number of subjects: 88
Study 34740836 — intervention group
Group type: EXPERIMENTAL
Intervention: MD at baseline followed by aPDT at baseline and at 3-month follow-up
Number of subjects: 88
Study 34740836 — intervention group
Group type: EXPERIMENTAL
Intervention: MD at baseline followed by aPDT at baseline and at 3- and 6-month follow-up
Number of subjects: 88
Study 33453159 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (CAG)
Number of subjects: 85
Study 33453159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) with postoperative interferon alfa‐2b (IFN alfa‐2b)
Number of subjects: 85
Study 33453159 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified conjunctival autograft plus amniotic membrane transplantation (mCAG plus AMT) with postoperative IFN alfa‐2b
Number of subjects: 85
Study 32713706 — intervention group
Group type: EXPERIMENTAL
Intervention: Live yeast culture
Number of subjects: 45
Study 32713706 — intervention group
Group type: COMPARATOR
Intervention: No yeast
Number of subjects: 45
Study 32713706 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfalfa haylage (AH)
Number of subjects: 45
Study 32713706 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn silage (CS)
Number of subjects: 45
Study 32713706 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass hay (GH)
Number of subjects: 45
Study 32713706 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage offered
Number of subjects: 45
Study 35344474 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hypnotic intervention for 7 weeks
Number of subjects: 20
Study 35344474 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 20
Study 34144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention group (counseling by primary care physicians and patient education pamphlets)
Number of subjects: 188
Study 34144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intervention group (only patient education pamphlets)
Number of subjects: 188
Study 34144695 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 188
Study 33109578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 569
Study 36058995 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ablation confirmation (AC) method for ablation applicator(s) placement verification and MAM assessment
Number of subjects: 100
Study 36058995 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection and anatomical landmarks-based quantitative measurements
Number of subjects: 100
Study 33549557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto)
Number of subjects: 3224
Study 35236723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance (arm B) including AFB every 6 months
Number of subjects: 364
Study 35236723 — intervention group
Group type: COMPARATOR
Intervention: Standard surveillance (arm A) with CT and AFB at 36 months
Number of subjects: 364
Study 35236723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild or moderate dysplasia at baseline bronchoscopy
Number of subjects: 364
Study 35236723 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 364
Study 33401126 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSRS application intervention for approximately 10 min/a day for 5 weeks
Number of subjects: 32
Study 33401126 — intervention group
Group type: COMPARATOR
Intervention: No intervention (wait list control group)
Number of subjects: 32
Study 35218033 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized plans without stopping criteria
Number of subjects: 10
Study 35218033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian plans without stopping criteria
Number of subjects: 10
Study 35218033 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized plans with stopping criteria
Number of subjects: 10
Study 35218033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian plans with stopping criteria
Number of subjects: 10
Study 35218033 — intervention group
Group type: COMPARATOR
Intervention: Manually generated plans
Number of subjects: 10
Study 32279518 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour comprehensive nutrition care (12h-HNC), n=158
Number of subjects: 312
Study 32279518 — intervention group
Group type: COMPARATOR
Intervention: Traditional one-time nutrition guidance (control group), n=154
Number of subjects: 312
Study 616406917 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg administered during 10 minutes before induction, then 15 mg/kg/hour during surgery)
Number of subjects: 110
Study 616406917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline administered in the same manner)
Number of subjects: 110
Study 616406917 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 110
Study 34129469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm-core TMAs using PD-1 NAT105 and PD-L1 28.8 antibodies with a 5% cut off for positivity on tumor-infiltrating immune cells (TILs) and tumor cells.
Number of subjects: 22
Study 34129469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mm-core TMAs
Number of subjects: 22
Study 34129469 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole tissue sections (WTS)
Number of subjects: 22
Study 35848047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with respiratory training
Number of subjects: 64
Study 35848047 — intervention group
Group type: COMPARATOR
Intervention: Routine swallowing rehabilitation training and respiratory training (Control)
Number of subjects: 64
Study 33303340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management intervention
Number of subjects: 60
Study 33303340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical detection threshold increase
Number of subjects: 60
Study 33303340 — intervention group
Group type: EXPERIMENTAL
Intervention: Windup ratio increase
Number of subjects: 60
Study 33303340 — intervention group
Group type: EXPERIMENTAL
Intervention: OXTR rs2254298 minor allele presence
Number of subjects: 60
Study 32491236 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill Denture Satisfaction Questionnaire (MDSQ) - overall satisfaction, retention/stability, aesthetics, cleaning, speech, comfort, general chewing ability
Number of subjects: 265
Study 32491236 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill Denture Satisfaction Questionnaire (MDSQ) - mastication of specific foods
Number of subjects: 265
Study 34811741 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive without life support (DAWOLS) at day 28 and 90
Number of subjects: 0
Study 34811741 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive and out of hospital (DAAOOH) at day 28 and 90
Number of subjects: 0
Study 34811741 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the EuroQol EQ-5D-5L questionnaire (EQ-VAS and EQ-5D-5L index values)
Number of subjects: 0
Study 33979372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining focusing on impact (group A)
Number of subjects: 0
Study 33979372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining focusing on cadence (group B)
Number of subjects: 0
Study 33979372 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study 35566210 — intervention group
Group type: EXPERIMENTAL
Intervention: BCP-SEDDS (100 mg)
Number of subjects: 24
Study 35566210 — intervention group
Group type: COMPARATOR
Intervention: BCP neat oil
Number of subjects: 24
Study 32301523 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb orthosis (Push Ortho and immediate fitting, IMF)
Number of subjects: 18
Study 32301523 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb-wrist orthosis (Ligaflex Manu and IMF)
Number of subjects: 18
Study 32301523 — intervention group
Group type: COMPARATOR
Intervention: Without orthosis
Number of subjects: 18
Study 32301523 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated orthoses
Number of subjects: 18
Study 33387724 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (400 mg) for 12–14 weeks
Number of subjects: 34
Study 33387724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg) for 12–14 weeks
Number of subjects: 34
Study 34775507 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 trials of self-selected AF triggers
Number of subjects: 446
Study 34775507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol exposure
Number of subjects: 446
Study 34775507 — intervention group
Group type: EXPERIMENTAL
Intervention: Other exposures (caffeine, etc.)
Number of subjects: 446
Study 34775507 — intervention group
Group type: COMPARATOR
Intervention: Control group (AF monitoring only)
Number of subjects: 446
Study 32374822 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID
Number of subjects: 448
Study 32374822 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 448
Study 32605809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Number of subjects: 57
Study 32605809 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 57
Study 32605809 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study 34762555 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate muscle damage group (MoDG) - 30 maximal eccentric isokinetic contractions at 60 degrees/s
Number of subjects: 30
Study 34762555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild muscle damage group (MiDG) - 10 maximal eccentric isokinetic contractions at 60 degrees/s
Number of subjects: 30
Study 34762555 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 30
Study 33492303 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg/d for 2 weeks
Number of subjects: 39
Study 33492303 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 39
Study 32794398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + citrate dentifrice A
Number of subjects: 120
Study 32794398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + sodium hexametaphosphate dentifrice B
Number of subjects: 120
Study 32794398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + pyrophosphate dentifrice C
Number of subjects: 120
Study 32794398 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate negative control
Number of subjects: 120
Study 36224697 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-process case management (group W)
Number of subjects: 204
Study 36224697 — intervention group
Group type: COMPARATOR
Intervention: Traditional perioperative case management (group G)
Number of subjects: 204
Study 34813408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaginal 17β-estradiol tablets
Number of subjects: 120
Study 34813408 — intervention group
Group type: COMPARATOR
Intervention: Vaginal promestriene cream
Number of subjects: 120
Study 34813408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 33517579 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative patient testimonials
Number of subjects: 334
Study 33517579 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-narrative decision strategies
Number of subjects: 334
Study 33517579 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated text)
Number of subjects: 334
Study 35621697 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA DQA1*03:01-B1*03:02 (DQ8/8)
Number of subjects: 670
Study 35621697 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA DQA1*03:03-B1*03:01
Number of subjects: 670
Study 35621697 — intervention group
Group type: EXPERIMENTAL
Intervention: DQ*VA
Number of subjects: 670
Study 35621697 — intervention group
Group type: EXPERIMENTAL
Intervention: DQ*AD
Number of subjects: 670
Study 35621697 — intervention group
Group type: EXPERIMENTAL
Intervention: VA/VA (DQA1*03:01-B1*03:02)
Number of subjects: 670
Study 34264825 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithms for predicting lung nodule malignancy from sequential LDCT scans
Number of subjects: 100
Study 34264825 — intervention group
Group type: COMPARATOR
Intervention: Volume change estimate
Number of subjects: 100
Study 36006643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 482
Study 36006643 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone with mycophenolate
Number of subjects: 482
Study 36006643 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of ESKD or 40% decline in eGFR
Number of subjects: 482
Study 36006643 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete and/or partial remission of proteinuria
Number of subjects: 482
Study 32801167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (10 mg, cumulative dose 3.5 mg/kg over 2 years)
Number of subjects: 3150
Study 32801167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3150
Study 34821063 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support
Number of subjects: 797
Study 34821063 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS support
Number of subjects: 797
Study 34821063 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 797
Study 33439486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib as second-line therapy
Number of subjects: 145
Study 33439486 — intervention group
Group type: COMPARATOR
Intervention: Fostamatinib as third-or-later-line therapy
Number of subjects: 145
Study 35766811 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 1120
Study 35766811 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg at week 0, week 4, then Q8W
Number of subjects: 1120
Study 35766811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to guselkumab at week 24)
Number of subjects: 1120
Study 33627111 — intervention group
Group type: EXPERIMENTAL
Intervention: MEBO ointment
Number of subjects: 0
Study 33627111 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem ointment
Number of subjects: 0
Study 33627111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEBO and Diltiazem ointments
Number of subjects: 0
Study 34310866 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringenin (NAR)
Number of subjects: 180